BioMedNewsBreaks Archive - Page 3 of 262

FridayApr 24, 2026 10:48 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Partnership Strategy to Advance Pipeline

Oncotelic Therapeutics (OTCQB: OTLC) provided a corporate update emphasizing its partnership-driven strategy to advance its oncology and rare disease pipeline and enhance shareholder value. The company cited its joint venture with GMP Biotechnology, which contributed to a $249.0 million increase in its balance sheet based on an independent third-party valuation, and said it is pursuing additional collaborations to support development and commercialization efforts. Management noted the approach is designed to advance multiple drug candidates in parallel while maintaining capital efficiency and unlocking the value of its intellectual property portfolio. To view the full press release, visit https://ibn.fm/gX9eb About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the…

FridayApr 24, 2026 9:20 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces $2.61M Private Placement and Warrant Inducement

Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has entered into a securities purchase agreement with institutional and accredited investors for the sale of 5,208,333 ADSs at $0.48 per ADS, along with accompanying Series A and Series B warrants, and separately executed a warrant inducement agreement with an existing investor. The combined transactions are expected to generate approximately $2.61 million in gross proceeds, with closing anticipated on or about April 27, 2026, subject to customary conditions. The company said proceeds will support expansion of its CDMO platform, advancement of customer programs and continued investment in its immunotherapy pipeline. To view the full…

ThursdayApr 23, 2026 12:33 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Collaborates to Advance Next-Gen ECG Solutions

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed its collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology. The publication indicates that the move, “highlights HeartBeam’s growing focus on artificial intelligence (‘AI’)-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward data-driven, remote monitoring solutions. The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate high value, AI-based ECG algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management.” To view the…

ThursdayApr 23, 2026 11:24 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In BioMedWire Editorial On Biotech Valuation Shift

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial examining how advancing drug pipelines are reshaping biotech valuations, as scientific progress is increasingly recognized as a measurable financial asset under evolving accounting frameworks. The piece highlights Oncotelic’s position at the intersection of oncology and AI-driven drug development, noting its diversified pipeline and strategic holdings, including a 45% stake in GMP Bio, as examples of how innovation and clinical advancement are being reflected in tangible enterprise value. To view the full press release, visit https://ibn.fm/JimL6 About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is…

ThursdayApr 23, 2026 9:40 am

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Adds Robert Langer, Stephen Brannan To Scientific Advisory Board

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its expertise in biotechnology, drug delivery and central nervous system clinical development as the company advances its pipeline of novel serotonergic agonists. The additions support Helus Pharma’s focus on disciplined, evidence-based drug development, including programs targeting major depressive disorder and generalized anxiety disorder, as it works to address unmet needs in mental health. To view the full press release, visit https://ibn.fm/CyjTq…

ThursdayApr 23, 2026 9:30 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Preclinical Immuno-Oncology Data At AACR 2026

Tonix Pharmaceuticals (NASDAQ: TNXP) announced new preclinical data from its immuno-oncology portfolio, including TNX-1700 and TNX-4700, presented through one oral and two poster sessions at the American Association for Cancer Research Annual Meeting 2026 in San Diego. The company reported findings supporting TNX-1700’s potential in reducing inflammation and tumor progression in gastric cancer models and demonstrating favorable pharmacokinetics, while TNX-4700 showed promising in vitro activity targeting BTLA, underscoring its potential as a cancer immunotherapy candidate alone or in combination with other checkpoint inhibitors. To view the full press release, visit https://ibn.fm/Oly6o Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals is a fully-integrated,…

WednesdayApr 22, 2026 2:54 pm

BioMedNewsBreaks — Perpetuals.com Ltd. (NASDAQ: PDC) Expands BayesShield AI Into Healthcare With Clinical Diagnostic Platform

Perpetuals.com (NASDAQ: PDC) announced the expansion of its BayesShield AI technology into healthcare with the launch of BayesShield Clinical, designed to identify physicians with the strongest diagnostic accuracy across specific case types. The platform applies the company’s statistical methodology, originally developed for financial markets, to reduce bias and improve clinical decision-making, with initial deployment supported through a partnership with the European Institute of Management to oversee pilot programs and academic validation. To view the full press release, visit https://ibn.fm/e91bm About Perpetuals Perpetuals.com Ltd (NASDAQ: PDC) is a fintech company developing AI-powered trading products and prediction markets, with a global footprint across the United States, Europe, and Asia. Its mission is to…

WednesdayApr 22, 2026 2:34 pm

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives Positive FDA Review Letter Supporting Ketamine ANDA Progress

NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a positive Discipline Review Letter from the FDA Office of Generic Drugs covering quality-related aspects of its ketamine ANDA, with only minor administrative updates requested. The company also reported a supportive meeting with FDA leadership aligned with federal priorities to accelerate treatments for severe mental illness, reinforcing expectations for potential approval of its preservative-free ketamine product in summer 2026. To view the full press release, visit https://ibn.fm/dL8aD About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders,…

WednesdayApr 22, 2026 2:17 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Highlights AVERSA Technology on Jack Neel Podcast

Nutriband (NASDAQ: NTRB) announced that CEO and Co-Founder Gareth Sheridan appeared on the Jack Neel Podcast to discuss the opioid crisis and the company’s AVERSA(TM) abuse-deterrent transdermal technology. The episode outlines how AVERSA(TM) is designed to reduce misuse, diversion, and accidental exposure of high-risk drugs such as fentanyl, while maintaining patient access, and is supported by a broad global patent portfolio. To view the full press release, visit https://ibn.fm/fSUKj About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into…

TuesdayApr 21, 2026 2:37 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights Capital Discipline as Critical to Biotech Success in Pharmaphorum Analysis

Dr. Christopher J. Schaber outlines strategies for navigating constrained funding environment Soligenix (NASDAQ: SNGX) CEO Dr. Christopher J. Schaber emphasized the importance of capital discipline in a Pharmaphorum analysis examining how biotech companies can succeed in today’s constrained funding environment, where even late-stage programs may struggle to secure investment. The article notes that strong science alone is no longer sufficient, with companies needing to align capital, execution and development strategy to achieve value-defining milestones that attract continued funding. The analysis describes capital discipline as an operating philosophy focused on directing resources toward key inflection points where data reduces uncertainty and increases program value, while also…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Partnership Strategy to Advance Pipeline

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces $2.61M Private Placement and Warrant Inducement

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Collaborates to Advance Next-Gen ECG Solutions

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In BioMedWire Editorial On Biotech Valuation Shift

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Adds Robert Langer, Stephen Brannan To Scientific Advisory Board

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Preclinical Immuno-Oncology Data At AACR 2026

BioMedNewsBreaks — Perpetuals.com Ltd. (NASDAQ: PDC) Expands BayesShield AI Into Healthcare With Clinical Diagnostic Platform

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives Positive FDA Review Letter Supporting Ketamine ANDA Progress

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Highlights AVERSA Technology on Jack Neel Podcast

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights Capital Discipline as Critical to Biotech Success in Pharmaphorum Analysis

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search